Samir Undevia | Edward-Elmhurst Health

Dr. Samir D. Undevia

Claim this profile

Elmhurst Memorial Hospital

Studies Melanoma
Studies Ovarian Cancer
5 reported clinical trials
26 drugs studied

Area of expertise

1Melanoma
Samir D. Undevia has run 3 trials for Melanoma. Some of their research focus areas include:
Stage IV
Stage III
2Ovarian Cancer
Samir D. Undevia has run 2 trials for Ovarian Cancer. Some of their research focus areas include:
BRCA1 positive

Affiliated Hospitals

Image of trial facility.
Elmhurst Memorial Hospital
Image of trial facility.
Edward Hospital/Cancer Center

Clinical Trials Samir D. Undevia is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Biomarker-Guided Immunotherapy Discontinuation

for Melanoma

This trial uses drugs that boost the immune system to fight advanced melanoma that can't be surgically removed. It aims to see if doctors can safely shorten the treatment period by using imaging tests to guide decisions. Pembrolizumab and ipilimumab are immunotherapy drugs used to treat advanced melanoma, with pembrolizumab approved for younger patients and ipilimumab showing positive results in previous studies.
Recruiting1 award Phase 222 criteria

More about Samir D. Undevia

Clinical Trial Related10 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Samir D. Undevia has experience with
  • Pembrolizumab
  • Bilateral Salpingectomy
  • Bilateral Salpingectomy With Oophorectomy
  • Afatinib
  • Binimetinib
  • Capivasertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Samir D. Undevia specialize in?
Is Samir D. Undevia currently recruiting for clinical trials?
Are there any treatments that Samir D. Undevia has studied deeply?
What is the best way to schedule an appointment with Samir D. Undevia?
What is the office address of Samir D. Undevia?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security